<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03236675</url>
  </required_header>
  <id_info>
    <org_study_id>ECT2015-003A</org_study_id>
    <nct_id>NCT03236675</nct_id>
  </id_info>
  <brief_title>Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients</brief_title>
  <official_title>Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exosome Diagnostics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exosome Diagnostics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate feasibility of detection of EML4-ALK fusion transcripts and T790M EGFR mutation
      from exosomes in the circulation of Non-Small Cell Lung Cancer (NSCLS) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is two-fold: 1) Demonstrate feasibility of detection of EML4-ALK
      fusion transcripts in the circulation of NSCLC patients positive for ALK on tissue analysis,
      using an institutionally accepted assay; 2) Demonstrate feasibility of detection of T790M
      EGFR mutation in the circulation of NSCLC patients positive for T790M on tissue analysis,
      using an institutionally accepted assay.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ALK mutation by tissue assay.</measure>
    <time_frame>Two years</time_frame>
    <description>Patients found to be positive for ALK mutation by tissue assay. ALK fusions in samples will be considered binary - positive or negative/ not assessable. 2x2 table will be constructed to determine concordance with tissue testing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T790M EGFR mutation by tissue assay</measure>
    <time_frame>Two years</time_frame>
    <description>Patients found to be positive for T790M EGFR mutation by tissue assay. ALK fusions in samples will be considered binary - positive or negative/ not assessable. 2x2 table will be constructed to determine concordance with tissue testing.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>EML4-ALK</arm_group_label>
    <description>ALK positive patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T790M EGFR</arm_group_label>
    <description>T790M positive patients</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      10-20 mL of whole blood collected in K2EDTA Plasma Preparation Tubes (PPT) will be acquired
      via standard venipuncture.

      This will be an observational study as subjects will only provide plasma specimens at
      different time points and no therapeutic or intervention will be received outside of their
      normal standard of care.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants must have histologically confirmed NSCLC, stage IIIB- IV, and have tested
             positive for the presence of EML4-ALK on tissue specimen, fresh or archived, using an
             institutionally accepted assay.

          2. Age of 18 years or older.

          3. Participants are being considered for ALK-directed therapy or have progressed on EGFR
             TKI treatment.

          4. Participants must have hemoglobin &gt; 10 mg/dL.

          5. Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Hepatitis (all types) in patient's medical record

          2. HIV documented in patient's medical record

          3. Hemoglobin &lt; 10 mg/dL

          4. Less than 18 years of age

          5. Histologically confirmed NSCLC Stage I-IIIA

          6. Tested negative for the presence of EML4-ALK and T790M EGFR on tissue
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Tun</last_name>
    <role>Study Director</role>
    <affiliation>Exosome Diagnostics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roger Tun</last_name>
    <phone>9149807318</phone>
    <email>Roger@exosomedx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Memorial Healthcare System</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nithya Sundararaman</last_name>
      <phone>954-265-1846</phone>
      <email>NSundararaman@mhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Campbell</last_name>
      <phone>954-265-6421</phone>
      <email>Kicampbell@mhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Luis E Raez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannine Ascani</last_name>
      <phone>504-842-8197</phone>
      <email>jeannine.ascani@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Sohail Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2017</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

